Posted by Michael Wonder on 28 Sep 2018
Lilly's Emgality (galcanezumab-gnlm) receives U.S. FDA approval for the preventive treatment of migraine in adults
27 September 2018 - Eli Lilly announced today that the U.S. FDA has approved Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.
Emgality offers a once-monthly, self-administered, subcutaneous injection. Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
The efficacy and safety of Emgality was demonstrated in two Phase 3 clinical trials in patients with episodic migraine (EVOLVE-1 and EVOLVE-2) and one Phase 3 clinical trial in patients with chronic migraine (REGAIN).
